The PD-1/PD-L1 Inhibitors Market Size is anticipated to be valued at US$ 49.5 billion in 2023, rising to US$ 123.3 billion by 2033. Over the forecast period, the market is expected to grow at a substantial CAGR of 9.6%.Because of the growing worldwide cancer burden, the usage of PD-1 and PD-L1 inhibitors, which are.
/PRNewswire/ The "PD-1 And PD-L1 Inhibitors Market by Application (solid tumors and blood-related tumors) and Geography (North America, Europe, Asia, and.
The market witnessed a slight decline in the sales of
ALK inhibitors in 2020 as several scheduled treatments were either delayed or postponed. Besides, the high incidence of COVID-19 in the second wave has limited the movement of people, which has disrupted the supply chain and logistic operations. These factors are expected to hinder the growth of the ALK inhibitors market to some extent during the forecast period.
The market is expected to be driven by factors such as the high target affinity and specificity of ALK inhibitors, the high prevalence of lung cancer, and the presence of patient assistance programs.